
aspergilloma
Sign in to saveAlso known as pulmonary aspergillosis
A pulmonary aspergilloma, also known as chronic pulmonary aspergillosis, is a human infectious disease of the lung caused by the colonization of a cavity by a fungus of the genus Aspergillus, most commonly Aspergillus fumigatus. The spores are transmitted through the air and are not contagious between individuals. It is a frequent complication of tuberculous cavities, which are themselves the primary sequelae of pulmonary tuberculosis, and correspond to localized lung tissue destruction. The cavities of pulmonary tubercles are poorly equipped to defend against Aspergillus infection, allowing t
Key facts
- Medical condition.name
- Aspergilloma
- Medical condition.synonyms
- Mycetoma, fungus ball, moldy lungs
- Medical condition.image
- Aspergillomas complicating tuberculosis.jpg
- Medical condition.caption
- Aspergillomas complicating tuberculosis: multiple aspergillomas within large cavitary lesions of tuberculous origin.
- Medical condition.field
- Infectious disease
- Medical condition.causes
- Aspergillus fungal infection
- Medical condition.diagnosis
- Chest x-ray show tumour like opacity. Serology can be helpful. Fungal hyphae seen on KoH mount and sputum culture grows fungus
via Wikipedia infobox
Health references
- ICD-10
- B44.0 — Invasive pulmonary aspergillosis
Research
2,039 papers- Aspergilloma and the surgeon.Journal of thoracic disease · 2014
- Aspergilloma.2026
- Endobronchial Aspergilloma.Respirology case reports · 2025
- Non-surgical treatment options for pulmonary aspergilloma.Respiratory medicine · 2020
- Endobronchial aspergilloma-a comprehensive literature review with focus on diagnosis and treatment modalities.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
via PubMed
Clinical Trials
8 registered- PHASE3RECRUITINGA Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary AspergillosisPost Graduate Institute of Medical Education and Research, Chandigarh · NCT06447402
- PHASE2/PHASE3UNKNOWNEfficacy of Intrabronchial Voriconazole Instillation for Inoperable Pulmonary AspergillomaAll India Institute of Medical Sciences · NCT03799809
- PHASE3RECRUITINGChronic Pulmonary Aspergillosis and Ambisome Aerosol with ItraconazolePoitiers University Hospital · NCT03656081
- UNKNOWNOutcome After Treatment of Pulmonary AspergillomaUniversity Hospital, Gasthuisberg · NCT01958710
- PHASE2COMPLETEDA Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of AspergillomaNational Institute of Allergy and Infectious Diseases (NIAID) · NCT00005668
- NAUNKNOWNThe Utility of Radiotherapy in the Management of Haemoptysis Secondary to Aspergillomata and Structural Lung DiseasesUniversity of Stellenbosch · NCT02878447
~23 min read
Encyclopedic overview
27 sectionsContents
- History
- Overview
- Causative organisms
- Predisposing conditions
- Pathophysiology
- Formation of tuberculous cavities
- Composition of an aspergilloma
- Mechanism of aspergilloma formation
- Clinical manifestations
- Diagnostic investigations
- Mycological diagnosis
- Pathogen identification
- Antifungal resistance
- Imaging
- Diagnostic approach
- Treatment
- Antifungal treatment
- Surgical indications
- Other treatments
- Considerations in Immunocompromised patients
- Prognosis and follow-up
- See also
- References
- Bibliography
- General articles
- Professional Society guidelines
- External links
A pulmonary aspergilloma, also known as chronic pulmonary aspergillosis, is a human infectious disease of the lung caused by the colonization of a cavity by a fungus of the genus Aspergillus, most commonly Aspergillus fumigatus. The spores are transmitted through the air and are not contagious between individuals. It is a frequent complication of tuberculous cavities, which are themselves the primary sequelae of pulmonary tuberculosis, and correspond to localized lung tissue destruction. The cavities of pulmonary tubercles are poorly equipped to defend against Aspergillus infection, allowing the fungus to proliferate and form a pseudo-tumor that partially fills the cavity. It is estimated that more than 370,000 people worldwide develop an aspergilloma each year.
Several forms of aspergilloma exist, with varying severity and symptoms depending on the patient's overall health. Aspergillomas are distinguished from other Aspergillus infections by their localized nature. They are categorized based on their size and the degree of underlying lung destruction. The primary complication is bleeding, which leads to expectoration of blood, sometimes life-threatening. Diagnosis is based on a combination of radiological findings and fungal identification. Treatment is either medical, using antifungals, or surgical.
Excerpted from Wikipedia’s “aspergilloma” article, available under the CC BY-SA 4.0 licence.